CRISPR Therapeutics (NASDAQ:CRSP) Releases Earnings Results, Beats Expectations By $0.71 EPS

CRISPR Therapeutics (NASDAQ:CRSP) announced its quarterly earnings data on Tuesday. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71, Zacks reports. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%.

CRISPR Therapeutics Price Performance

CRSP opened at $39.62 on Wednesday. The stock has a market capitalization of $3.38 billion, a price-to-earnings ratio of -14.00 and a beta of 1.67. The business has a 50-day moving average of $42.45 and a two-hundred day moving average of $46.40. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

CRSP has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on shares of CRISPR Therapeutics in a research report on Monday, February 3rd. They issued a “buy” rating and a $65.00 target price on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $86.00 target price on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Bank of America decreased their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Monday, December 30th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $94.00 target price on shares of CRISPR Therapeutics in a research report on Tuesday, December 10th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $75.22.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.